Sanofi Cuts Development Of 14 Drugs In First Quarter, With More R&D Changes To Come
This article was originally published in The Pink Sheet Daily
Executive Summary
Among halted development programs is Phase III antidepressant saredutant; decision on Plavix follow-on idrabiotaparinux awaits FDA safety determination.
You may also be interested in...
Pfizer Halts Phase III Figitumumab Trial In NSCLC, But Other Studies Go On
News that Pfizer was discontinuing a Phase III study of the insulin growth factor-1 receptor inhibitor figitumumab in non-small cell lung cancer didn't come as much of a surprise Dec. 30. The firm had already announced in October it was suspending patient enrollment after more participants died following treatment with the drug than without
Pfizer Halts Phase III Figitumumab Trial In NSCLC, But Other Studies Go On
News that Pfizer was discontinuing a Phase III study of the insulin growth factor-1 receptor inhibitor figitumumab in non-small cell lung cancer didn't come as much of a surprise Dec. 30. The firm had already announced in October it was suspending patient enrollment after more participants died following treatment with the drug than without
Pfizer Halts Phase III Figitumumab Trial In NSCLC But Forges On With Other Studies
Insulin growth factor-1 receptor inhibitor is one of Pfizer's lead oncology candidates, but the company is not throwing in the towel on figitumumab yet.